Ginkgo Bioworks Holdings, Inc.
NYSE:DNABiotechnology
+$0.26 today
- Market cap
- $547.12M
- Beta
- 1.80
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.11
Volume 2.36M
Average 1.24M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
Intrinsic Alpha fair value
Locked
Current Price
$8.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -29.1% | +21.4% (4yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -29.1% over three years. Forward estimates point to Revenue at +21.4% (4yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Iovance Biotherapeutics, Inc. NASDAQ:IOVA | $3.59B | $7.76 | Not rated | -4.6 | +230.97% |
MBX Biosciences, Inc. Common Stock NASDAQ:MBX | $2.78B | $55.94 | Not rated | -22.0 | +95.03% |
Replimune Group, Inc. NASDAQ:REPL | $2.08B | $21.89 | Not rated | -3.0 | +120.36% |
Vir Biotechnology, Inc. NASDAQ:VIR | $1.71B | $9.96 | Not rated | -3.0 | +68.20% |
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | $1.13B | $7.54 | Not rated | -7.1 | +110.86% |
MeiraGTx Holdings plc NASDAQ:MGTX | $881.67M | $9.18 | Not rated | -7.4 | +9.76% |
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | $672.92M | $13.01 | Not rated | -9.8 | -45.58% |
Valneva SE NASDAQ:VALN | $538.42M | $5.66 | Not rated | -2.9 | -38.62% |
Arvinas, Inc. NASDAQ:ARVN | $446.61M | $6.82 | Not rated | -2.2 | -41.33% |
Continue the stock analysis
Jump to another research area for this company.